Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ilkova, H.
Right arrow Articles by Shepherd, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ilkova, H.
Right arrow Articles by Shepherd, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Guest editorial

Hasan Ilkova1, Terje R. Pedersen2 and James Shepherd3

1 Istanbul University Cerrahpasa Medical School, Istanbul, Turkey
2 Ullevål University Hospital, Oslo, Norway
3 Glasgow Royal Infirmary, Glasgow, UK

The first 10% of the full text of this article appears below.

The rate of advance of cardiovascular clinical research in recent years has been astounding. A decade ago, the Scandinavian Simvastatin Survival Study and the West of Scotland Coronary Prevention Study had recently reported. These trials and the other landmark studies that followed ushered in the statin era, having demonstrated beyond doubt the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?